MELOXICAM MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global Meloxicam Market Size and Forecast: 2025 to 2032

The global meloxicam market is estimated to be valued at USD 8.15 Bn in 2025 and is expected to reach USD 12.34 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032. This steady growth is driven by increasing incidences of chronic inflammatory diseases and a growing elderly population seeking effective pain management solutions. Expansion in emerging markets and advancements in drug formulation are also contributing to market growth during this period.

Key Takeaways of the Global Meloxicam Market

• The tablets segment is expected to lead the global meloxicam market, holding a 52.1% share in 2025.
• Osteoarthritis segment is estimated to dominate the market, accounting for 41.1% share in 2025.
• The 7.5 mg segment is projected to dominate the meloxicam market, capturing a 44.6% share in 2025
• North America is expected to lead the market, holding a share of 39.6% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with an estimated market share of 24.4% in 2025.

Market Overview

The market trend for meloxicam highlights a shift towards sustained-release formulations and combination therapies aimed at improving patient compliance and reducing side effects. Additionally, there is a rising preference for oral care therapy over injectable forms, driven by convenience and cost-effectiveness.

Pharmaceutical companies are investing in research to enhance bioavailability and minimize gastrointestinal risks, aligning with the increasing patient demand for safer, long-term anti-inflammatory medications. Digital healthcare integration and personalized treatment regimens further support market evolution.

Currents Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Meloxicam Market Insights, By Product Type - Tablets Contribute the Highest Share of the Market Owing to Patient Convenience and Manufacturing Advantages

Tablets capture the largest share of the global meloxicam market with an estimated share of 52.1% in 2025, because it is easily administered and has a perfect dosing effect. Tablets provide an oral route and are therefore very ideal in chronic illnesses like arthritis which need long-term and regular medication schedules. Tablets are self-administered unlike injectable solutions that may require professionals to administer, thus enhancing patient compliance especially in outpatient and home-care care.

Examples of companies producing or supplying meloxicam tablets include Sun Pharmaceutical Industries Ltd., which markets meloxicam tablets under the brand name “Muvera.” Cipla Ltd. also offers meloxicam in tablet form, notably under the brand name “Melflam.” Dr. Reddy's Laboratories Ltd. is another key player in the market, providing meloxicam tablets among their NSAID offerings.

Meloxicam Market Insights, By Indication - Osteoarthritis Leads Owing to its High Prevalence and the Chronic Need for Effective Pain Management

Osteoarthritis segment is projected to account for 41.1% of the market share in 2025. It is rather common and one of the most prevalent types of arthritis which leads to progressive degeneration of the joint as well as the chronic pain, and the aging population is mainly concerned.

With age and changing lifestyles, involving a rise in sedentary activities, the rates of osteoarthritis will only continue to rise, and numerous longer-term, more effective ways of managing the symptoms should be provided.

Meloxicam Market Insights, By Dosage Strength - 7.5 mg Holds the Highest Share Attributable to Optimized Efficacy and Safety for Long-Term Use

The 7.5 mg segment is expected to capture 44.6% of the global meloxicam market share in 2025, which is a balanced response to high effectiveness in controlling the symptoms and the least adverse effects possible.

This dose is usually the best starting point, which provides good anti-inflammatory effects, and has good safety profile, particularly in patients with arthritis who have comorbidities. Clinicians choose to start at 7.5 mg because titration can be done depending on the individual patient response and tolerability.

Prevalence and Incidence of Osteoarthritis, Rheumatoid Arthritis, and Musculoskeletal Pain Disorders by Region

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Regional Insights

To learn more about this report, Download Free Sample

North America Meloxicam Market Analysis and Trends

The North America region is projected to lead the market with a 39.6% share in 2025, because of robust presence of the pharmaceutical industry and developed research and development facilities. The area enjoys tight regulatory measures including those practiced by the FDA which guarantees the quality and safety of medicines which makes the healthcare professionals and patients to trust the health care service providers.

Additionally, the increasing level of chronic inflammation conditions and growing number of older age groups present the need to utilize powerful NSAIDs, such as Meloxicam. There is a huge presence of major pharmaceuticals such as Pfizer, Teva Pharmaceuticals, and Mylan who invest heavily in the improvement and uptake of product innovation.

Asia Pacific Meloxicam Market Analysis and Trends

The meloxicam market in Asia Pacific is the fastest growing market because of the increasing access to healthcare with an estimated share of 24.4% in 2025, the growing awareness about treatment, and the escalating rate of lifestyle-related disorders. As other emerging economies like India and China invest in health infrastructure and introduce conducive government policies to improve access to drugs, the market is changing very fast.

Moreover, there are many generic drug manufacturers and contract research organizations increasing the production capacity and causing cost-effective offerings. Such companies as Sun Pharmaceutical Industries, Lupin and Aurobindo Pharma have key roles in enhancing the regional coverage of meloxicam.

Meloxicam Market Outlook for Key Countries

U.S. Meloxicam Market Trends

The U.S. market of meloxicam is one of the major revenue generators of meloxicam due to its well-developed healthcare system and high amounts of research and development funds among the major pharmaceutical industries like Pfizer and Mylan. Insurance coverage of treatments of chronic inflammation as well as patient awareness programs help to adopt it on a broad market. The policies of the federal and state governments promote innovation and high standards of drug safety.

Another major company is Amgen that specializes in biologics and inflammatory treatments to complement the traditional market of NSAIDs such as meloxicam. Another pharmaceutical company, Endo Pharmaceuticals, also offers its own generic versions, which are relatively cheap to patients with chronic pains.

Germany Meloxicam Market Trends

Germany is dominant in Europe meloxicam market and this is backed by an efficient healthcare environment, sound reimbursement regulations and strict regulatory supervision by the European Medicines Agency (EMA). The pharmaceutical industry of the country is characterized by innovations and high-quality production, and such companies as Bayer and Zentiva are taking an active part in Meloxicam-based treatment. Aging and increased healthcare spending are other factors which facilitate long term demand.

The interest of Merck Group in the market of meloxicam is carried out in the form of its healthcare unit, which produces innovative treatment solutions to inflammatory diseases. Another product with meloxicam in its line is Stada Arzneimittel AG; it specializes in producing high-quality generic products in European countries.

China Meloxicam Market Trends

The meloxicam market in China is still growing at a very fast pace, the government has been taking moves to make sure that more people are accessing the necessary medications and also improving the healthcare facilities. Jiangsu Hengrui Medicine and CSPC Pharmaceutical Group are big players in the generic manufacturing industry in the country, and they play a major role in making meloxicam more affordable and accessible. The increased incidence of the chronic diseases and a growth in healthcare expenditure favor a fast growth in the market.

The availability of branded and generic meloxicam has also increased the market share of Shanghai Fosun Pharmaceutical which has created a more accessible drug in the Chinese market. Another noteworthy player is Hainan Poly Pharm, which contributes to the supply of meloxicam in the country.

India Meloxicam Market Trends

India’s meloxicam market benefits from a combination of a vast patient population and a highly competitive pharmaceutical manufacturing base. Indian companies like Sun Pharma, Lupin, and Aurobindo Pharma are notable contributors, focusing on both domestic demand and exports. Government policies promoting pharmaceutical growth and the "Pharma Vision 2020" initiative encourage enhanced drug research and manufacturing capabilities.

Dr. Reddy’s Laboratories plays a significant role in India's meloxicam market by offering generic and cost-effective versions for treating conditions like arthritis. Cadila Healthcare also manufactures meloxicam, targeting both domestic and international markets with its affordable solutions.

Adverse Events & Comparative Safety/Efficacy of Meloxicam vs NSAIDs

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In August 2025, Viatris Inc., a global healthcare company, announced positive results from its Phase 3 trials of MR-107A-02, a fast-acting meloxicam formulation for treating moderate-to-severe acute pain. The trials demonstrated statistically significant pain improvement compared to placebo in herniorrhaphy and bunionectomy surgeries. MR-107A-02 also showed a notable reduction in opioid usage, with more opioid-free patients than the placebo group.
• In June 2025, Azurity Pharmaceuticals announced U.S. FDA approval of XIFYRM, a novel injectable meloxicam formulation for managing moderate‑to‑severe pain in adults. XIFYRM delivers once‑daily dosing via IV injection and offers a non‑opioid alternative suitable alone or combined with other analgesics. The approval could strengthen meloxicam’s role in acute pain management globally.
• In March 2025, Zoetis announced the results of the first clinical trial comparing Librela (bedinvetmab) to meloxicam for managing canine osteoarthritis (OA) pain. The study found that Librela provided equivalent pain relief to meloxicam while being associated with fewer adverse events. The trial, conducted across eight veterinary practices in the U.K., involved 101 dogs and showed that both treatments improved pain over the eight-week period.
• In December 2020, Lupin Limited, a global pharmaceutical company, launched meloxicam capsules (5 mg and 10 mg) after receiving approval from the U.S. FDA. These capsules are a generic equivalent of Vivlodex Capsules from Zyla Life Sciences, and are indicated for managing osteoarthritis (OA) pain. With annual U.S. sales of approximately USD 11 million, meloxicam capsules aim to provide an affordable alternative for OA pain relief.

Top Strategies Followed by Global Meloxicam Market Players

• Well-established pharmaceutical companies are at the forefront with high levels of investment in research and development (R&D) in the quest to come up with high-performance meloxicam preparations with better efficacy, safety levels, and adherence by the patient. These market participants enter into strategic alliances with OEMs to improve its manufacturing capacity and increase its product range. They emphasize international growth, penetrating the new markets with increasing demand on the anti-inflammatory products, and promoting growth and revenues.
  • Pfizer and Mylan (Viatris) dominate the meloxicam market through substantial R&D investments, developing high-performance formulations to improve efficacy, safety, and patient adherence. They have formed strategic partnerships with OEMs to boost manufacturing capabilities and expand their product portfolios globally.
• Mid-level players in the meloxicam market mostly focus on offering pharmaceutical options that are effective and affordable, striking a balance between the quality and cost. Operating largely in the price-sensitive market segment, including the developing economies, or the uninsured groups, these firms maintain the strategy of focusing more on minimized production cost, without impairing clinical effect.
  • Cipla and Zydus Cadila focus on offering cost-effective meloxicam solutions, catering primarily to price-sensitive consumers in emerging economies. These companies adopt strategies to optimize production costs while ensuring the clinical efficacy of their products, making them accessible to uninsured populations and developing markets.

• Small-scale competitors are becoming agile competitors by cutting niches of meloxicam market through innovation and localization. These companies put money in the development of differentiated or reformulated products, e.g. tailored dosages, innovative drug delivery routes, or natural preparations, to address certain patient requirements that can be missed by larger firms.
  • MediPoint Pharma and Lupin Pharmaceuticals are examples of small-scale players carving out specialized niches in the meloxicam market. They focus on innovation through customized dosages and novel drug delivery systems, addressing specific patient needs that are often overlooked by larger pharmaceutical giants.

Market Report Scope

Meloxicam Market Dynamics

To learn more about this report, Download Free Sample

Meloxicam Market Driver - Increasing Prevalence of Arthritis and Musculoskeletal Disorders

The rising rate of occurrence of arthritis and other musculoskeletal diseases across the globe is one of the major forces behind the meloxicam market across the world. With the aging of the population, the cases of chronic joint diseases like osteoarthritis and rheumatoid arthritis are constantly rising, resulting in the necessity to develop a more efficient management of pain and anti-inflammatory levels. Meloxicam is a selective COX-2 inhibitor with a targeted response, which decreases inflammation and pain and has a relatively good gastrointestinal safety profile, which health care professionals prefer. Besides, lifestyle changes, sedentary life, and obesity also lead to an increase in musculoskeletal disorders, and long-term treatment options are extended.

In June 2025, a global study from MJH Life Sciences, highlighted the rising prevalence of musculoskeletal disorders (MSDs) in postmenopausal women In 2021, over 210 million postmenopausal women globally were affected by musculoskeletal disorders (MSDs), contributing to nearly 45 million DALYs. Osteoarthritis (OA) continues to be a significant burden, with 50% of postmenopausal women, Globally, the prevalence of OA in 2021 reached 606.5 million, a sharp increase from 256 million in 1990. Additionally, there were 46.6 million new OA cases in 2021 alone, with knee OA accounting for 374.7 million prevalent cases and 30.85 million incident cases worldwide. These figures highlight the growing global burden of MSDs, particularly among postmenopausal women.

Meloxicam Market Opportunity - Development of Fixed-Dose Combinations with Gastroprotective Agents

Global meloxicam market offers a great growth potential by developing fixed-dose combinations (FDC) of gastroprotective agents to meet an urgent requirement of improved safety profiles when NSAIDs are used chronically. The selective-COX-2 inhibitor (Meloxicam) is an extremely popular agent that has been used to control osteoarthritis and rheumatoid arthritis, but has a risk of gastrointestinal (GI) adverse effects, such as ulcers and bleeding especially in extended schedules. The combination of gastroprotective medications like proton pump inhibitors (PPIs) or H2 receptor antagonists in the same dosage form not only makes the treatment regimens simpler, but also enhances patient compliance and patient outcomes through reduction of GI complications.

For example, Axsome Therapeutics is developing AXS-06, a fixed-dose combination of its proprietary “MoSEIC” reformulated Meloxicam + Esomeprazole (a PPI). AXS‑06 aims to deliver rapid pain relief while reducing the risk of NSAID‑induced gastrointestinal ulcers exactly tapping the market‑opportunity you outlined.

Analyst Opinion (Expert Opinion)

• The increasing rate of osteoarthritis and rheumatoid arthritis, especially in old age, is contributing to the growth of meloxicam market. The patient adherence and patient outcomes are being enhanced by technological advancements, such as fixed-dose combinations (FDCs) of gastroprotective agents. Market growth has also been enhanced by regulatory support. Nevertheless, the main question is how to balance efficacy and safety particularly when it comes to gastrointestinal risks and long-term use of NSAIDs.
• Some of the important conferences, including the Annual American College of Rheumatology Meeting and the International Conference on Pain Research, have played a central role in the discussions on pain management treatment such as meloxicam. Particular advancements, such as AXS-06 by Axsome Therapeutics, which is a combination of meloxicam and esomeprazole, will provide a resolution to the issue of safety and might shape the trends in the market.

Market Segmentation

• Product Type Insights (Revenue, USD Bn, 2020 - 2032)
• • Tablets
  • Capsules
  • Syrup or Oral Suspension
  • Injectable Solutions
• Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Osteoarthritis
  • Rheumatoid arthritis
  • Juvenile rheumatoid arthritis (pediatric arthritis)
  • Other musculoskeletal or inflammatory disorders
• Dosage Strength Insights (Revenue, USD Bn, 2020 - 2032)
  • 5 mg
  • 15 mg
  • Other strengths (e.g., 5 mg, 10 mg)
• Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Parenteral
• Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Branded
  • Generic
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Adults
  • Pediatric
  • Geriatric
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals and Clinics
  • Specialty Clinics
  • Homecare Settings
  • Research and Academic Institutes
  • Others (long-term care, nursing homes, etc.)
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Cipla Ltd
  • Unichem Laboratories Ltd
  • Cadila Pharmaceuticals Ltd
  • Lupin Ltd
  • Aurobindo Pharma Ltd
  • Reddy's Laboratories Ltd
  • Olon S.p.A
  • Dishman Carbogen Amcis
  • Rochem International Inc
  • HELM Portugal
  • Hoventa Pharma
  • Cerata Pharmaceuticals LLP
  • Darshan Pharma Chem
  • Zeon Pharma Industries India Pvt Ltd
  • Swati Spentose

Sources

Primary Research Interviews

Industry Stakeholders

• Pharmacists
• API Suppliers
• Formulators
• Generic drug manufacturers
• Distributors
• Healthcare providers (pain management)

End users

• Rheumatologists
• Orthopedic specialists
• General practitioners
• Patients (chronic pain, arthritis)
• Hospital formulary managers
• Patients using NSAIDs (survey interviews)

Government and International Databases

• WHO Global Health Observatory
• FDA Drug Approvals Database
• National Institute for Health and Care Excellence (NICE)
• U.S. Centers for Disease Control and Prevention (CDC)
• European Medicines Agency (EMA)
• U.S. National Library of Medicine (PubMed)

Trade Publications

• Pharmaceutical Technology
• Journal of Pharmaceutical Sciences
• European Journal of Pharmaceutical Sciences
• Drug Development and Industrial Pharmacy
• The Pharmaceutical Journal
• Pharmaceutical Business Review

Academic Journals

• Journal of Pharmacology and Experimental Therapeutics
• European Journal of Clinical Pharmacology
• Clinical Pharmacokinetics
• The Lancet (Pharmacology & Drug Safety)
• Journal of Pain Research
• Rheumatology International

Reputable Newspapers

• The New York Times (Health section)
• The Guardian (Health & Science section)
• The Washington Post (Health section)
• BBC News (Health & Medicine)
• Reuters Health News
• The Financial Times (Health and Drug Policy)

Industry Associations

• World Health Organization (WHO)
• U.S. Food and Drug Administration (FDA)
• American College of Rheumatology
• European Medicines Agency (EMA)
• International Pharmaceutical Federation (FIP)
• American Pain Society

Public Domain Resources

• DrugBank
• National Institutes of Health (NIH) Repositories
• U.S. National Library of Medicine (NLM)
• ClinicalTrials.gov
• VigiBase (WHO’s Pharmacovigilance Database)

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years